early-stage first-in-class non-intoxicating cannabinoid therapeutics
Farbod Parvin
Founder & Chief Executive Officer, THCA Therapeutics
Preclinical evidence completed.
Now advancing to Phase 0/1.
THCA Therapeutics has completed its core preclinical evidence program for THCA PURE™ Oral, spanning five animal models and more than 30 published studies. The company is now finalizing GMP manufacturing and regulatory documentation ahead of its first-in-human Phase 0/1 study.
Chronic inflammatory disease is a growing global crisis.
Chronic inflammatory and autoimmune diseases are rising worldwide, driving significant human suffering and escalating healthcare costs. Current therapies often carry meaningful side effects or fail to address the underlying inflammation — leaving a large and growing need for safer, better-tolerated options.
A distinct opportunity in non-intoxicating medicine.
Tetrahydrocannabinolic acid (THCA) is a naturally occurring, non-psychoactive cannabinoid investigated for multi-target activity across inflammation, immune regulation, oxidative stress, and cellular protection.
Non-intoxicating profile
THCA is the acidic precursor of THC and does not produce psychoactive effects before decarboxylation.
Multi-target biology
Engages PPARγ, NF-κB, and cytokine pathways implicated in inflammatory signaling and immune regulation.
Preclinical foundation
30+ published studies across inflammation, neuroprotection, metabolism, and immune-related models.
Pharmaceutical potential
Converting promising research into stable, standardized, quality-controlled therapies for clinical evaluation.
Consistent findings across multiple disease models.
Preclinical studies report reductions in inflammatory markers and improvements in functional outcomes across several animal models. All figures below are preclinical (animal-model) findings, not clinical results.
Rheumatoid Arthritis Model
Neuroprotection Model
Neurodegeneration Model
Respiratory Inflammation Model
One platform. Multiple therapeutic opportunities.
THCA Therapeutics is developing a pharmaceutical platform built around high-purity, stabilized THCA formulations for different routes of administration.
THCA PURE™ Oral
A pharmaceutical-grade oral capsule engineered to prevent decarboxylation and deliver consistent, non-intoxicating systemic THCA exposure.
- Pharmaceutical-grade THCA isolate
- Precise, standardized dosing
- Proprietary stabilization technology
- Preclinical studies completed
THCA PURE™ Inhale
A jet-milled, dry-powder inhaler platform intended for fast-onset, targeted respiratory and systemic support.
- Dry powder inhaler (DPI) format
- Non-combustible, non-vaporized
- Shared science & manufacturing base
- Currently under development
Current therapies often mean a difficult trade-off.
Conventional and biologic therapies have transformed care for many patients with rheumatoid arthritis and other chronic inflammatory diseases — but they frequently come with real trade-offs.
Conventional DMARDs
Drugs such as methotrexate are commonly associated with gastrointestinal and liver-related side effects and require ongoing monitoring.
Biologic therapies
TNF-α inhibitors and JAK inhibitors carry elevated infection risk and, for some classes, cardiovascular warnings — and are typically delivered by injection or infusion.
Treatment cycling
Many patients try multiple therapies before finding one that is both effective and tolerable, adding cost and burden to daily life.
THCA Therapeutics is investigating whether a non-intoxicating, orally administered cannabinoid could offer a different tolerability profile for patients living with chronic inflammatory disease — a hypothesis that has not yet been tested in human clinical trials.
A platform designed for defensibility and quality.
From day one, THCA Therapeutics is building both the legal protection and the manufacturing discipline a pharmaceutical platform requires.
Intellectual Property Strategy
We are building a multi-layered IP portfolio to protect our platform technologies, formulations, and manufacturing processes across key markets.
Manufacturing Quality
Every stage of production — from raw material sourcing to packaging — is designed to meet GMP standards, in partnership with certified manufacturing and testing partners.
A disciplined, milestone-driven path forward.
"My personal health journey inspired this mission. The science drives it forward. Patients are why we exist."
THCA Therapeutics was founded to bring rigorous, pharmaceutical-grade science to a compound with a promising but under-explored profile. Our mission is to become a globally recognized biotechnology company that translates cannabinoid science into safe, effective, non-intoxicating therapies for patients with high unmet needs.
Read our full story →